24 reports

  • PRESCRIPTION LANDSCAPE FOR OTHER CLASSES 2015
  • Lipid Modifying Drug
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi S.A.

Fish Oil Supplement and Fenofibrate on Triglyceride (TG) Levels in Subjects on Highly Active Antiretroviral Therapy (HAART) Who Are Not Responding to Either Fish Oil or Fenofibrate Alone The Effect of Fish Oil Plus Fenofibrate on Triglyceride Lev

  • Cardiovascular Disease
  • Clinical Trial
  • Endocrine Disease
  • Lipid Modifying Drug
  • AstraZeneca PLC
  • Clinical Trial profile. 1201 Trial Title
  • 5. All the trials included are unique trials.
  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Pharmaceutical
  • World
  • Target
  • Clinical Trial profile. 240 Trial Title
  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Pharmaceutical
  • World
  • Target
  • Cardiovascular Disease
  • Clinical Trial
  • Hospital
  • Lipid Modifying Drug
  • World
  • 10.4 JAPAN
  • NIACIN/NICOTINIC ACID SWOT ANALYSIS, 2015

" Fish oil' s mechanism of action is good.

  • Lipid Modifying Drug
  • AstraZeneca PLC
  • Cerenis
  • Merck & Co., Inc.
  • The Medicines Company

This allows for enhanced bioavailability and EPA and DHA blood levels compared to the " esterified" fish-oil omega-## options such as LOVAZA.

  • Cholesterol
  • Chronic Disease
  • Lipid Modifying Drug
  • Pharmaceutical
  • Esperion Therapeutics, Inc.

Fish Oil Inhibition of Stenosis in Haemodialysis Grafts Study Fish Oil Inhibition of Stenosis in Haemodialysis Grafts Study GDCT## ISRCTN##, MCT ## Cardiovascular Chronic Kidney Disease (Chronic Renal Failure), Coronary Stenosis, End-Stage Kidney Dis

  • Drug Discovery And Development
  • Lipid Modifying Drug
  • Statins
  • World
  • Product Initiative

fish oil Shiraz University of Medical Sciences Shahid Beheshti University of Medical Sciences ## Feb 2012 ## Mar 2013 ## ## ## Official Title Clinical Trial profile. ## Trial Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial Phase Study Type Drug(s)

  • Lipid Modifying Drug
  • Therapy
  • World
  • Product Initiative
  • Pfizer Inc.

Oil or Olive Oil, on Lipid Parameters, Vascular Risk Markers Blood Pressure and Endothelial Function, in Moderately Hypercholesterolemic Subjects Effects of Corn Oil Plus Vitamin E and B## on Lipids, PcSk## and Endothelial Function (ECLIPSE) GDCT## NCT##, ECLIPSE_

  • Cardiovascular Disease
  • Clinical Trial
  • Hospital
  • Lipid Modifying Drug
  • World
  • Target
  • Cardiovascular Disease
  • Chronic Disease
  • Lipid Modifying Drug
  • Pharmaceutical
  • World

Fish Oil Supplement and Fenofibrate on Triglyceride (TG) Levels in Subjects on Highly Active Antiretroviral Therapy (HAART) Who Are Not Responding to Either Fish Oil or Fenofibrate Alone The Effect of Fish Oil Plus Fenofibrate on Triglyceride Lev

  • Clinical Trial
  • Lipid Modifying Drug
  • Pharmaceutical
  • World
  • Product Initiative
  • Clinical Trial Profile Snapshots

Seeds Oil in Healthy Volunteers: A Randomized, Double-blind, Placebo-controlled Clinical Trial Hypolipidemic Effects of Nigella Sativa L.

  • Cardiovascular Disease
  • Clinical Trial
  • Drug Discovery And Development
  • Lipid Modifying Drug
  • World

Fish Oil Pilot Trial The Chronic Obstructive Pulmonary Disease Fish Oil Pilot Trial (COD-Fish) GDCT## NCT##, AAAC##; P##ES## Cardiovascular Chronic Obstructive Pulmonary Disease (COPD), Endothelial Dysfunction (Interferon Gamma (Immune Int

  • Cardiology
  • Clinical Trial
  • Hospital
  • Lipid Modifying Drug
  • World
  • 5. All the trials included are unique trials.

Fish Oil Supplementation on Postprandial Lipid Metabolism in Familial Hypercholesterolaemia Postprandial Lipid Metabolism in Familial Hypercholesterolaemia:Effects of Fish Oils (FIFH) GDCT## NCT##, NHMRC## Metabolic Disorders Familial Hypercholesterolemia (

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • World
  • Product Initiative
  • NIASPAN (NIACIN EXTENDED-RELEASE) SWOT ANALYSIS, 2014
  • 9.4.2 PERCENT DRUG-TREATED PATIENTS

Competitive Assessment MAJOR FISH OIL-DERIVED OMEGA-##S: EICOSAPENTAENOIC ACID (EPA) AND DOCOSAHEXAENOIC ACID (DHA).

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Clinical Trial Profile Snapshots

Fish Oil Efficacy Study on the Lipid-lowering Effect of Plant Sterols and Fish Oil GDCT## NCT##, ##V Metabolic Disorders Hypercholesterolemia (High Density Lipoprotein Cholesterol (HDL-C), Low Density Lipoprotein (LDL)) Completed Phase III Interventi

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • World
  • Merck & Co., Inc.

This allows for enhanced bioavailability and EPA and DHA blood levels compared to the " esterified" fish-oil omega-## options such as LOVAZA.

  • Chronic Disease
  • Lipid Modifying Drug
  • United States
  • World
  • Product Initiative

Omega-##-Carboxylic Acids is a complex mixture of concentrated omega-## free fatty acids purified from crude marine fish oil.

  • Endocrine Disease
  • Lipid Modifying Drug
  • United States
  • Company
  • Product Initiative
  • OMEGA-3-CARBOXYLIC ACIDS - DRUG PROFILE

The trial evaluated ## patients in four dosing groups: Epanova ##g/ day, Epanova ##g/ day, Epanova ##g/ day and control (olive oil ##g/ day).

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • United States
  • Company
  • Product Initiative
  • 8.1.1 FORECAST
  • NIASPAN (NIACIN EXTENDED-RELEASE) SWOT ANALYSIS, 2014

EZETIMIBE CONTRIBUTED ##% ($##M), LEAVING ABOUT ##. ##% TO THE OMEGA-## FISH OIL DRUGS ($##M).

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • NIASPAN (NIACIN EXTENDED-RELEASE) SWOT ANALYSIS, 2014
  • 9.4.2 PERCENT DRUG-TREATED PATIENTS

Competitive Assessment MAJOR FISH OIL-DERIVED OMEGA-##S: EICOSAPENTAENOIC ACID (EPA) AND DOCOSAHEXAENOIC ACID (DHA).

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • NIASPAN (NIACIN EXTENDED-RELEASE) SWOT ANALYSIS, 2014
  • 9.4.2 PERCENT DRUG-TREATED PATIENTS

Competitive Assessment MAJOR FISH OIL-DERIVED OMEGA-##S: EICOSAPENTAENOIC ACID (EPA) AND DOCOSAHEXAENOIC ACID (DHA).

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • GLAXOSMITHKLINE'S DYSLIPIDEMIA PORTFOLIO ASSESSMENT, 2014
  • HIGHLIGHTS GSK'S CURRENT PORTFOLIO OF DYSLIPIDEMIA THERAPEUTICS.
  • Lipid Modifying Drug
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.